Ertapenem-resistant enterobacteriaceae: Risk factors for acquisition and outcomes

Infection Control and Hospital Epidemiology

Volumn 31, Issue 12, 2010, Pages 1242-1249

  Hyle, E P ^a   Ferraro, M J ^a   Silver, M ^a   Lee, H ^a   Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM; ERTAPENEM;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CASE CONTROL STUDY; CENTRAL VENOUS CATHETERIZATION; CONTROLLED STUDY; DEATH; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ERTAPENEM RESISTANT ENTEROBACTERIACEAE; FEMALE; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; URBAN AREA; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; BOSTON; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EQUIPMENT CONTAMINATION; FEMALE; HOSPITALS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; URBAN POPULATION; YOUNG ADULT;

EID: 78649940501     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/657138     Document Type: Article

References (38)

1. Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-166.
2. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 2006;35(5 suppl 1):S20-S28.
3. Nicasio AM, Kuti JL, Nicolau DP. The current state ofmultidrug-resistant gram-negative bacilli in North America. Pharmacotherapy 2008;28(2): 235-249.
4. Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect 2002;8(6):321-331.
5. MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SG, Gould IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet 1997;350(9080):783.
6. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005;49(7): 3018-3020.
7. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165(12):1430-1435. (Pubitemid 40973427)
8. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51(8):3026- 3029. (Pubitemid 47206254)
9. Nardkarni AS, Schliep T, Khan L, Zeana CB. Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan. Am J Infect Control 2009;37(2):121-126.
10. Woodford N, Tierno PM, Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC- 3, in a New York medical center. Antimicrob Agents Chemother 2004;48(12): 4793-4799. (Pubitemid 39577686)
11. Woodford N, Zhang J, Warner M, et al. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J Antimicrob Chemother 2008;62(6):1261-1264.
12. Peirano G, Seki LM, Val Passos VL, Pinto MC, Guerra LR, Asensi MD. Carbapenem-hydrolysing b-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil. J Antimicrob Chemother 2009;63(2): 265-268.
13. Samuelson O, Naseer U, Tofteland S, et al. Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. J Antimicrob Chemother 2009;63(4):654-658.
14. Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58(10):256-260.
15. McGettigan SE, Andreacchio K, Edelstein PH. Specificity of ertapenem susceptibility screening for detection of Klebsiella pneumoniae carbapenemases. J Clin Microbiol 2009;47(3):785-786.
16. Knaus WA, Drapier EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
17. Richter SS, Ferraro MJ. Susceptibility testing instrumentation and computerized expert systems for data analysis and interpretation. In:Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of Clinical Microbiology. 9th ed. Washington, DC: American Society for Microbiology, 2007:245-256.
18. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing - 19th informational supplement. Wayne, PA: CLSI; 2009. CLSI document M100-S19.
19. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests: approved standard M2-A10. Wayne, PA: CLSI; 2009. CLSI document M2-A10.
20. Jacoby GA. AmpC b-lactamases. Clin Microbiol Rev 2009;22(1):161-182.
21. Bradford P, Urban C, Mariano N, Projan S, Rahal J, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC b-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;41(3):563-569.
22. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition onmortality. Antimicrob Agents Chemother 2008;52(3):1028-1033.
23. Kwak YG, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11(2):165-169. (Pubitemid 40705827)
24. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009;30(7):666-671.
25. Jeon MH, Choi SH, Kwak YG, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis 2008;62(4):402-406.
26. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007;60(5):1124-1130. (Pubitemid 47617764)
27. Gasink L, Edelstein P, Lautenbach E, Synnestvedt M, Fishman N. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase- producing K. pneumoniae. Infect Control Hosp Epidemiol 2009;30(12): 1180-1185.
28. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29(12):1099-1106.
29. Hyle EP, Bilker WB, Gasink LB, Lautenbach E. Impact of different methods for describing the extent of prior antibiotic exposure on the association between antibiotic use and antibiotic-resistant infection. Infect Control Hosp Epidemiol 2007;28(6):647-654. (Pubitemid 46954748)
30. Poirel L, Heritier C, Spicq C, Nordmann P. In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clin Microbiol 2004; 42(8):3831-3833.
31. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 2006;50(9):3098-3101.
32. Hong T, Moland ES, Abdalhamid B, et al. Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis 2005;40(10): e84-e86.
33. Gulmez D, Woodford N, Palepou MF, et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA- 48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents 2008;31(6):523-526.
34. Miriagou V, Tzelepi E, Gianneli D, Tzouvelekis LS. Escherichia coli with a self-transferable, multiresistant plasmid coding for metallo-β-lactamase VIM-1. Antimicrob Agents Chemother 2003;47(1):395-397.
35. Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006;12(8):1209-1213.
36. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007;45(8):2723-2725.
37. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis 2002;34(12):1558-1563. (Pubitemid 34615439)
38. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010;50(3):364-373.